Menu
Search
|

Menu

Close
X

ArQule Inc ARQL.OQ (NASDAQ Stock Exchange Global Market)

10.53 USD
-0.38 (-3.48%)
As of Jul 23
Previous Close 10.91
Open 11.03
Volume 355,702
3m Avg Volume 718,165
Today’s High 11.07
Today’s Low 10.49
52 Week High 12.21
52 Week Low 2.23
Shares Outstanding (mil) 119.73
Market Capitalization (mil) 1,306.29
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
26
FY17
0
FY16
5
EPS (USD)
FY19
-0.094
FY18
-0.154
FY17
-0.392
FY16
-0.326
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
56.87
8.16
Price to Book (MRQ)
vs sector
16.74
4.43
Price to Cash Flow (TTM)
vs sector
--
24.27
Total Debt to Equity (MRQ)
vs sector
20.88
17.60
LT Debt to Equity (MRQ)
vs sector
16.77
12.56
Return on Investment (TTM)
vs sector
-31.95
12.67
Return on Equity (TTM)
vs sector
-47.58
17.18

EXECUTIVE LEADERSHIP

Patrick Zenner
Independent Chairman of the Board, Since 2004
Salary: --
Bonus: --
Peter Lawrence
President, Chief Operating Officer, Since 2008
Salary: $458,591.00
Bonus: $206,579.00
Paolo Pucci
Chief Executive Officer, Director, Since 2008
Salary: $506,302.00
Bonus: $303,971.00
Marc Schegerin
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Brian Schwartz
Chief Medical Officer, Since 2008
Salary: $456,521.00
Bonus: $182,797.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Wall St Fl 6
BURLINGTON   MA   01803-4757

Phone: +1781.9940300

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

SPONSORED STORIES